Objective: Given evidence for clustering of signalling molecules and ion channels in cholesterol-rich membrane domains, the involvement of such structures in arteriolar smooth muscle mechanotransduction was examined. Method: To determine the contribution of smooth muscle cholesterol-rich membrane domains to the myogenic response, isolated arterioles were exposed to the cholesterol-depleting agent β-cyclodextrin (1–10 mM) in the absence and presence of excess exogenous cholesterol. Results: β-Cyclodextrin significantly impaired pressure-induced vasoconstriction, while excess cholesterol attenuated this effect. Impaired myogenic constriction was evident in de-endothelialized vessels, indicating an action at the level of smooth muscle. β-Cyclodextrin treatment uncoupled increases in intracellular Ca2+ from myogenic constriction and depleted intracellular Ca2+ stores consistent with a loss of connectivity between plasma membrane and sarcoplasmic reticulum signalling. However, β-cyclodextrin-treated arterioles showed unaltered constrictor responses to KCl and phenylephrine. Electron microscopy verified that β-cyclodextrin caused a decrease in caveolae, while confirmation of smooth muscle containing caveolae was obtained by immunostaining for caveolin-1. Viability of β-cyclodextrin-treated arterioles was confirmed by agonist sensitivity and propidium iodide nuclear staining. Conclusion: The data suggest that smooth muscle cholesterol-rich membrane domains contribute to the myogenic response. Further studies are required to determine whether this relates to specific mechanosensory events or generalized alterations in membrane function.

Keywords:
Arterioles, Mechanotransduction, Cholesterol, membrane, Ca2+, Contraction
1.
Davis MJ, Donovitz JA, Hood JD: Stretch-activated single-channel and whole cell currents in vascular smooth muscle cells. Am J Physiol 1992;262:C1083–C1088.
2.
Knot HJ, Nelson MT: Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure. J Physiol 1998;508(part 1):199–209.
3.
Davis MJ, Hill MA: Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999;79:387–423.
4.
Martinez-Lemus LA, Wu X, Wilson E, Hill MA, Davis GE, Davis MJ, Meininger GA: Integrins as unique receptors for vascular control. J Vasc Res 2003;40:211–233.
5.
Zou H, Ratz PH, Hill MA: Role of myosin phosphorylation and [Ca2+]i in myogenic reactivity and arteriolar tone. Am J Physiol 1995;269:H1590–H1596.
6.
Zou H, Ratz PH, Hill MA: Temporal aspects of Ca2+ and myosin phosphorylation during myogenic and norepinephrine-induced arteriolar constriction. J Vasc Res 2000;37:556–567.
7.
Gokina NI, Osol G: Actin cytoskeletal modulation of pressure-induced depolarization and Ca2+ influx in cerebral arteries. Am J Physiol Heart Circ Physiol 2002;282:H1410–H1420.
8.
Lagaud G, Gaudreault N, Moore ED, Van Breemen C, Laher I: Pressure-dependent myogenic constriction of cerebral arteries occurs independently of voltage-dependent activation. Am J Physiol Heart Circ Physiol 2002;283:H2187–H2195.
9.
Schubert R, Kalentchuk VU, Krien U: Rho kinase inhibition partly weakens myogenic reactivity in rat small arteries by changing calcium sensitivity. Am J Physiol Heart Circ Physiol 2002;283:H2288–H2295.
10.
Flavahan NA, Bailey SR, Flavahan WA, Mitra S, Flavahan S: Imaging remodeling of the actin cytoskeleton in vascular smooth muscle cells after mechanosensitive arteriolar constriction. Am J Physiol Heart Circ Physiol 2005;288:H660–H669.
11.
Shaul PW, Anderson RG: Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998;275:L843–L851.
12.
Parton RG: Caveolae – from ultrastructure to molecular mechanisms. Nat Rev Mol Cell Biol 2003;4:162–167.
13.
Bergdahl A, Sward K: Caveolae-associated signalling in smooth muscle. Can J Physiol Pharmacol 2004;82:289–299.
14.
Palade GE: Fine structure of blood capillaries. J Appl Physiol 1953;24:1424.
15.
Everson WV, Smart EJ: Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med 2001;11:246–250.
16.
Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, Alexander RW: Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 2001;276:48269–48275.
17.
Shaw L, Sweeney MA, O’Neill SC, Jones CJ, Austin C, Taggart MJ: Caveolae and sarcoplasmic reticular coupling in smooth muscle cells of pressurised arteries: the relevance for Ca2+ oscillations and tone. Cardiovasc Res 2006;69:825–835.
18.
Lohn M, Furstenau M, Sagach V, Elger M, Schulze W, Luft FC, Haller H, Gollasch M: Ignition of calcium sparks in arterial and cardiac muscle through caveolae. Circ Res 2000;87:1034–1039.
19.
Pike LJ, Miller JM: Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. J Biol Chem 1998;273:22298–22304.
20.
Meininger GA, Zawieja DC, Falcone JC, Hill MA, Davey JP: Calcium measurement in isolated arterioles during myogenic and agonist stimulation. Am J Physiol 1991;261:H950–H959.
21.
Hill MA, Zou H, Davis MJ, Potocnik SJ, Price S: Transient increases in diameter and [Ca2+]i are not obligatory for myogenic constriction. Am J Physiol Heart Circ Physiol 2000;278:H345–H352.
22.
Neild TO: Measurement of arteriole diameter changes by analysis of television images. Blood Vessels 1989;26:48–52.
23.
Potocnik SJ, Murphy TV, Kotecha N, Hill MA: Effects of mibefradil and nifedipine on arteriolar myogenic responsiveness and intracellular Ca2+. Br J Pharmacol 2000;131:1065–1072.
24.
Jackson WF, Huebner JM, Rusch NJ: Enzymatic isolation and characterization of single vascular smooth muscle cells from cremasteric arterioles. Microcirculation 1997;4:35–50.
25.
Richards K, Davis MJ, Potocnik SJ, Murphy TV, Bishara NB, Rajanayagam MA, Darby IA, Hill MA: Approaches for introducing peptides into intact and functional arteriolar smooth muscle: manipulation of protein kinase-based signalling. Clin Exp Pharmacol Physiol 2003;30:653–658.
26.
Levitan I, Christian AE, Tulenko TN, Rothblat GH: Membrane cholesterol content modulates activation of volume-regulated anion current in bovine endothelial cells. J Gen Physiol 2000;115:405–416.
27.
Dreja K, Voldstedlund M, Vinten J, Tranum-Jensen J, Hellstrand P, Sward K: Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arterioscler Thromb Vasc Biol 2002;22:1267–1272.
28.
Cheng X, Jaggar JH: Genetic ablation of caveolin-1 modifies Ca2+ spark coupling in murine arterial smooth muscle cells. Am J Physiol Heart Circ Physiol 2006;290:H2309-H2319.
29.
Cohen AW, Hnasko R, Schubert W, Lisanti MP: Role of caveolae and caveolins in health and disease. Physiol Rev 2004;84:1341–1379.
30.
Yu J, Bergaya S, Murata T, Alp IF, Bauer MP, Lin MI, Drab M, Kurzchalia TV, Stan RV, Sessa WC: Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest 2006;116:1284–1291.
31.
Darblade B, Caillaud D, Poirot M, Fouque M, Thiers JC, Rami J, Bayard F, Arnal JF: Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc Res 2001;50:566–576.
32.
Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001;293:2449–2452.
33.
Je HD, Gallant C, Leavis PC, Morgan KG: Caveolin-1 regulates contractility in differentiated vascular smooth muscle. Am J Physiol Heart Circ Physiol 2004;286:H91–H98.
34.
Jackson WF, Blair KL: Characterization and function of Ca2+-activated K+ channels in arteriolar muscle cells. Am J Physiol 1998;274:H27–H34.
35.
Kotecha N, Hill MA: Myogenic contraction in rat skeletal muscle arterioles: smooth muscle membrane potential and Ca2+ signaling. Am J Physiol Heart Circ Physiol 2005;289:H1326–H1334.
36.
Potocnik SJ, Hill MA: Pharmacological evidence for capacitative Ca2+ entry in cannulated and pressurized skeletal muscle arterioles. Br J Pharmacol 2001;134:247–256.
37.
Bishara NB, Murphy TV, Hill MA: Capacitative Ca2+ entry in vascular endothelial cells is mediated via pathways sensitive to 2 aminoethoxydiphenyl borate and xestospongin C. Br J Pharmacol 2002;135:119–128.
38.
Murphy TV, Spurrell BE, Hill MA: Tyrosine phosphorylation following alterations in arteriolar intraluminal pressure and wall tension. Am J Physiol Heart Circ Physiol 2001;281:H1047–H1056.
39.
Spurrell BE, Murphy TV, Hill MA: Intraluminal pressure stimulates MAPK phosphorylation in arterioles: temporal dissociation from myogenic contractile response. Am J Physiol Heart Circ Physiol 2003;285:H1764–H1773.
40.
Zeidan A, Broman J, Hellstrand P, Sward K: Cholesterol dependence of vascular ERK1/2 activation and growth in response to stretch: role of endothelin-1. Arterioscler Thromb Vasc Biol 2003;23:1528–1534.
41.
Sedding DG, Hermsen J, Seay U, Eickelberg O, Kummer W, Schwencke C, Strasser RH, Tillmanns H, Braun-Dullaeus RC: Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circ Res 2005;96:635–642.
42.
Osol G, Brekke JF, McElroy-Yaggy K, Gokina NI: Myogenic tone, reactivity, and forced dilatation: a three-phase model of in vitro arterial myogenic behavior. Am J Physiol Heart Circ Physiol 2002;283:H2260–H2267.
43.
Cipolla MJ, Osol G: Vascular smooth muscle actin cytoskeleton in cerebral artery forced dilatation. Stroke 1998;29:1223–1228.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.